Approval · Notice of Compliance 35241 · 2025
TEVA-MORPHINE SR: Notice of Compliance 35241
Issued April 22, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35241
- Date
- April 22, 2025
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph
- Canadian reference product
- MS CONTIN (Purdue Pharma)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-MORPHINE SR | Not yet assigned | — |
Medicinal ingredients
- MORPHINE SULFATE 15 MG per TAB
- MORPHINE SULFATE 30 MG per TAB
- MORPHINE SULFATE 60 MG per TAB
- MORPHINE SULFATE 100 MG per TAB
- MORPHINE SULFATE 200 MG per TAB